Follicular Non-Hodgkin's Lymphoma Refractory

Follicular Non-Hodgkin's Lymphoma Refractory is the indication for 2 drugs in DrugBank. It is covered by 2 curated, structured indications.

Also known as: refractory follicular Non-Hodgkin's lymphoma · refractory follicular non-hodgkin lymphoma
Classified under: Hemic and Lymphatic Diseases
Immunoproliferative Disorders
Lymphatic Disorders
Neoplasms
Indicated drugs: Bendamustine
Ibritumomab tiuxetan

What you can answer from here — as of November 13, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

1Clinical trialPhase, status and sponsor resolved per trial

Which approved drugs for Follicular Non-Hodgkin's Lymphoma Refractory share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.